Lebrikizumab Gets the Nod for Treating Moderate-to-Severe At

Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.

Related Keywords

Germany , United States , Eli Lilly , Drug Administration , European Commission , New England Journal , Global Assessment , Dermatitis , Europe , European , Biologic Therapy , Atopic Dermatitis , Topical Corticosteroids , Corticosteroid , Interleukins , Ocular Allergies , Llergic Eye Diseases , Llergic Ophthalmologic Conditions , Corneal Disease , Allergic Conjunctivitis , Conjunctivitis , Adolescent Medicine , Eczema , Monoclonal Antibody , Etuximab , Ituximab , Severity Indices , Topical Therapy ,